Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s share price hit a new 52-week low during trading on Monday . The company traded as low as $9.61 and last traded at $9.69, with a volume of 20,242 shares. The stock had previously closed at $10.15.

A number of research analysts have recently weighed in on the company. HC Wainwright assumed coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 18th. They issued a “neutral” rating and a $10.00 price objective for the company. Piper Jaffray Cos. initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “overweight” rating and a $20.00 price objective for the company. Wedbush initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating and a $18.00 price objective for the company. Cowen and Company initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating for the company. Finally, JMP Securities initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, July 25th. They issued an “outperform” rating and a $22.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $17.50.

The firm’s 50 day moving average is $0.00 and its 200-day moving average is $0.00. The stock’s market capitalization is $89.67 million.

In related news, Director Robert Nelsen bought 400,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The stock was purchased at an average price of $12.50 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Redmile Group, Llc bought 432,746 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The stock was bought at an average price of $12.50 per share, with a total value of $5,409,325.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.